CXCR3, a double-edged sword in tumor progression and angiogenesis
Authors:
- Cathy QuemenerCQCathy Quemener
- Andreas BikfalviABAndreas Bikfalvi
- 1 December 2013
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1836 (2) , 287-295
Abstract
No abstract availableKeywords
This publication has 82 references indexed in Scilit:
- Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammationProceedings of the National Academy of Sciences, 2012
- Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3British Journal of Pharmacology, 2011
- CXCR3 in T cell functionExperimental Cell Research, 2011
- Expression and agonist responsiveness of CXCR3 variants in human T lymphocytesImmunology, 2011
- Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide AntagonistsScience, 2010
- Chemokine receptor CXCR3 promotes growth of gliomaCarcinogenesis, 2010
- CXCR3-B Can Mediate Growth-inhibitory Signals in Human Renal Cancer Cells by Down-regulating the Expression of Heme Oxygenase-1Journal of Biological Chemistry, 2010
- Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungsInternational Journal of Cancer, 2009
- TNF-α and the IFN-γ-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastomaCancer Gene Therapy, 2008
- CXCR3 Requires Tyrosine Sulfation for Ligand Binding and a Second Extracellular Loop Arginine Residue for Ligand-Induced ChemotaxisMolecular and Cellular Biology, 2006